Tisdag 9 Juni | 15:09:37 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-10 07:30 Bokslutskommuniké 2026
2026-11-03 07:30 Kvartalsrapport 2026-Q3
2026-08-13 07:30 Kvartalsrapport 2026-Q2
2026-05-08 - X-dag ordinarie utdelning RAY B 4.00 SEK
2026-05-07 - Årsstämma
2026-04-29 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-07 - Kvartalsrapport 2025-Q3
2025-08-08 - Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning RAY B 3.00 SEK
2025-05-22 - Årsstämma
2025-05-09 - Kvartalsrapport 2025-Q1
2025-02-21 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag bonusutdelning RAY B 1.3
2024-05-23 - X-dag ordinarie utdelning RAY B 0.70 SEK
2024-05-22 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning RAY B 0.00 SEK
2023-05-25 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2022-05-25 - Årsstämma
2022-05-18 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2021-05-26 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning RAY B 0.00 SEK
2020-06-30 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning RAY B 0.00 SEK
2019-05-21 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning RAY B 0.00 SEK
2018-05-29 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-24 - X-dag ordinarie utdelning RAY B 0.00 SEK
2017-05-23 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-18 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-18 - X-dag ordinarie utdelning RAY B 0.25 SEK
2016-05-17 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-29 - X-dag ordinarie utdelning RAY B 0.00 SEK
2015-05-28 - Årsstämma
2015-05-08 - Kvartalsrapport 2015-Q1
2015-02-12 - Bokslutskommuniké 2014
2014-11-27 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-05-28 - X-dag ordinarie utdelning RAY B 0.00 SEK
2014-05-27 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-13 - Bokslutskommuniké 2013
2013-11-27 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-05-23 - X-dag ordinarie utdelning RAY B 0.00 SEK
2013-05-22 - Årsstämma
2013-05-16 - Kvartalsrapport 2013-Q1
2013-02-14 - Bokslutskommuniké 2012
2012-11-16 - Kvartalsrapport 2012-Q3
2012-08-28 - Kvartalsrapport 2012-Q2
2012-05-31 - X-dag ordinarie utdelning RAY B 0.00 SEK
2012-05-30 - Årsstämma
2012-05-23 - Kvartalsrapport 2012-Q1
2012-02-16 - Bokslutskommuniké 2011
2011-11-24 - Kvartalsrapport 2011-Q3
2011-05-26 - X-dag ordinarie utdelning RAY B 0.50 SEK
2011-05-25 - Årsstämma
2011-05-04 - Kvartalsrapport 2011-Q1
2011-02-18 - Bokslutskommuniké 2010
2010-11-12 - Kvartalsrapport 2010-Q3
2010-08-27 - Kvartalsrapport 2010-Q2
2010-05-26 - X-dag ordinarie utdelning RAY B 0.50 SEK
2010-05-25 - Årsstämma
2010-05-11 - Kvartalsrapport 2010-Q1
2009-11-20 - Kvartalsrapport 2009-Q3
2009-08-27 - Kvartalsrapport 2009-Q2
2009-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2009-05-26 - Årsstämma
2009-05-15 - Kvartalsrapport 2009-Q1
2008-06-25 - Split RAY B 1:3
2003-06-10 - Split RAY B 20:1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
RaySearch Laboratories är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av mjukvara för strålbehandling av cancer. Bolagets produkter riktar sig till sjukvårdsinstitutioner och onkologer. Verksamheten är internationell och riktar sig till kunder runtom den globala marknaden. RaySearch Laboratories grundades 2000 och har sitt huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-05 09:35:00

RaySearch Laboratories AB (publ) will highlight new advances in particle therapy at PTCOG 64 in Deauville, Normandy, France, June 9–12. At booth #06, visitors can explore the company’s latest software developments, book demonstrations, and learn more about RaySearch’s solutions via the PTCOG event page.

Advancing reirradiation in particle therapy
RaySearch will highlight enhanced support for reirradiation planning and evaluation in the upcoming RayStation release.* Reirradiation means treating a patient again in an area that has already received radiation, which can be challenging due to the dose already delivered to healthy organs. RayStation helps clinics manage this by combining dose from previous and current treatments and making it easier to evaluate the total impact.

The system uses advanced image registration and EQD2 calculations to provide a clearer view of the accumulated dose, taking into account different tissue types and cell recovery over time. Since particle therapy is the most conformal type of radiation, it is particularly well suited for reirradiation treatments which are fundamentally constrained by the cumulative dose to healthy tissues. RayStation can include prior dose directly in the optimization process, helping clinicians balance protecting healthy organs with delivering effective treatment to the target.

Other highlights
RaySearch will have a broad presence at PTCOG 64, and host an annual particle therapy user meeting in conjunction with the conference. PhD students and researchers from RaySearch will also present scientific posters and give presentations. In addition, RaySearch will continue its engagement in UniteRT, reinforcing its commitment to open, vendor-agnostic ecosystems that promote collaboration, choice, and innovation in radiotherapy.

More information about RaySearch’s activities at the event is available here:
RaySearch PTCOG 2026 Event Page
UniteRT Website

“Reirradiation is an area of increasing importance in radiation oncology, where better planning software can make a real difference for clinics and patients,” says Johan Löf, founder and CEO of RaySearch Laboratories. “With the upcoming RayStation release, we are advancing treatment planning in proton therapy and building on our leading position in this growing and strategically important field.”

For more information, please contact:
Matt Miley, Head of Marketing, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
marketing@raysearchlabs.com

Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation® treatment planning system and the oncology information system RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RaySearch’s software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

Läs mer om oss på:
LinkedIn
YouTube

RaySearch products are subject to regulatory clearance in some markets.
*This functionality is investigational, not CE-marked or FDA-cleared, and is not available for clinical use.